On December 13, 2022 WuXiDiagnostics, an enabling platform company that implements integrated diagnostics and Abcam (AIM:ABC; NASDAQ:ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, reported that a new supply and licensing agreement in the area of companion diagnostic reagents to support the development of innovative anti-cancer treatments in China (Press release, Abcam, DEC 13, 2022, View Source [SID1234625168]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The rapid development of targeted cancer immunotherapy in the past decade has accelerated the need for accurate and efficient companion diagnostic tests for biomarker status assessment. At patient selection, the detection of disease-related biomarkers helps to identify individuals that may respond to a certain targeted therapy, thereby supporting safe and effective treatment. During treatment, companion diagnostic tests provide vital pharmacodynamic data on how patients respond.
Building on their existing relationship, this new collaboration leverages Abcam’s industry-leading antibody development capabilities, combined with WuXiDiagnostics’ long-standing research and development expertise in the area of companion diagnostics. The two parties will join forces to comprehensively assist drug development and diagnostic tools, to continue to fuel the growth of the life science industry and enable the faster delivery of positive outcomes for science and health.
Yin Wang, Senior Director of pharma company service and Companion Diagnostics at WuXiDiagnostics, said: "Since its foundation, developing companion diagnostic reagents with pharmaceutical partners has been one of WuXiDiagnostics‘ major strategies. This whole process relies on excellent antibody quality and supply chain stability. I am very happy that WuXiDiagnostics has established a long-term strategic cooperation with Abcam, one of the world’s top antibody manufacturers. Together we are poised to deliver the best solutions for the clinical progression of anti-cancer drugs and the application of precision medicine."
Emma Sceats, SVP Sales, Service & Business Development at Abcam, said: "I am excited that we are further developing our cooperation with WuXiDiagnostics. With our combined expertise, Abcam and WuXiDiagnostics will enable the biopharma industry to achieve fast advances and develop innovative medicine that has the potential to benefit more people in China."